Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
Christopher J SweeneyIvor J PercentSunil BabuJennifer L CultreraBryan A MehlhaffOscar B GoodmanDavid S MorrisIan D SchnadigCostantine AlbanyNeal D ShorePaul R SieberSusan C GubaWei ZhangVolker WacheckGregory P DonohoAnna M SzpurkaSophie CalliesBoris Kin LinJohanna C BendellPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Samotolisib/enzalutamide has tolerable side effects and significantly improved PFS in patients with mCRPC with cancer progression on abiraterone, and this may be enriched in patients with PTEN intact and no androgen receptor splice variant 7.